Skip to content

Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery

Pilot Evaluation of Cosmetic Outcome and Surgical Site Infection Rates of Coated VICRYL* Plus Antibacterial (Polyglactin 910) Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00768222
Enrollment
101
Registered
2008-10-08
Start date
2008-10-31
Completion date
2009-05-31
Last updated
2011-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

wound healing

Brief summary

This is a 90-day study to evaluate cosmetic outcome and Surgical Site Infection in approximately 100 patients from 6 centers in China undergoing scheduled modified radical mastectomy for breast cancer.

Detailed description

Patients will be evaluated post-procedure on Days 3, 5, 7, 12, 30 and 90 for cosmetic outcome and surgical site infection.

Interventions

skin closure

DEVICEVICRYL* Plus suture

skin closure

Sponsors

Johnson & Johnson Medical, China
CollaboratorINDUSTRY
Ethicon, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age or older with written informed consent * Scheduled for a modified radical mastectomy * Surgical wound classified Class I/Clean using the CDC SSI Surgical Wound Classification

Exclusion criteria

* Unable to give consent and unlikely to comply with study requirements and complete the 90-day follow up visit * Undergoing surgery for modified radical mastectomy with immediate breast reconstruction, cosmetic breast operations, reduction, expansion, insertion of prothesis, duct ectasia or infective breast disease or implant * Surgical wounds classified as Class II, III or IV using CDC SSI Surgical Wound Classification * Has inflammatory cancers or skin ulceration * Has known allergy or intolerance to triclosan * Has compromised wound healing or chronic immune deficiency, for example diabetes, prolonged steroid use, AIDS or substance abuse * Has serious heart and/or lung disease * Has skin scar history or family history * Has direct relationship to or involvement in this or other studies under the direction of the investigator or center * Received an experimental drug or device within 30 days prior to the planned start of treatment

Design outcomes

Primary

MeasureTime frameDescription
Mean Score on Cosmetic Outcome Visual Analog Scale (VAS)30 days (+/- 5) post-operativePost-operative cosmetic outcome assessed on surgical site photographs by an independent blinded central assessor using a validated 100 mm visual analog scale, with 0 representing the worst possible scar and 100 representing the best possible scar

Secondary

MeasureTime frameDescription
Mean Cosmetic Outcome Score on Modified Hollander Scale12 daysPost-operative cosmetic outcome assessed on surgical site by investigator using the modified Hollander Cosmetic Scale (mHCS) with 0 representing worst and 6 representing best, calculated by adding the individual scores on each of 6 categories (step-off borders, contour irregularities, wound margin separation, edge inversion, excessive inflammation, and overall appearance
Mean Surgical Site Infection Score on Modified ASEPSIS ScaleDay 3Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst)

Countries

China

Participant flow

Participants by arm

ArmCount
Chinese Silk Suture
Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern
50
VICRYL* Plus Suture
Synthetic absorbable surgical suture composed of a copolymer of 90% glycolide and 10% L-lactide and containing triclosan antibacterial, used in a subcuticular closure technique
51
Total101

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up11
Overall StudyProtocol Violation02
Overall StudyWithdrawal by Subject31

Baseline characteristics

CharacteristicChinese Silk SutureVICRYL* Plus SutureTotal
Age Continuous52.2 years
STANDARD_DEVIATION 10.3
53.0 years
STANDARD_DEVIATION 12.1
52.6 years
STANDARD_DEVIATION 11.2
Region of Enrollment
China
50 participants51 participants101 participants
Sex: Female, Male
Female
50 Participants51 Participants101 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
14 / 507 / 51
serious
Total, serious adverse events
3 / 501 / 51

Outcome results

Primary

Mean Score on Cosmetic Outcome Visual Analog Scale (VAS)

Post-operative cosmetic outcome assessed on surgical site photographs by an independent blinded central assessor using a validated 100 mm visual analog scale, with 0 representing the worst possible scar and 100 representing the best possible scar

Time frame: 30 days (+/- 5) post-operative

Population: Intention to treat (ITT)

ArmMeasureValue (MEAN)Dispersion
Chinese Silk SutureMean Score on Cosmetic Outcome Visual Analog Scale (VAS)45.4 score on scaleStandard Deviation 12
VICRYL* Plus SutureMean Score on Cosmetic Outcome Visual Analog Scale (VAS)67.2 score on scaleStandard Deviation 18.2
Secondary

Mean Cosmetic Outcome Score on Modified Hollander Scale

Post-operative cosmetic outcome assessed on surgical site by investigator using the modified Hollander Cosmetic Scale (mHCS) with 0 representing worst and 6 representing best, calculated by adding the individual scores on each of 6 categories (step-off borders, contour irregularities, wound margin separation, edge inversion, excessive inflammation, and overall appearance

Time frame: 12 days

Population: Intention to treat (ITT)

ArmMeasureValue (MEAN)Dispersion
Chinese Silk SutureMean Cosmetic Outcome Score on Modified Hollander Scale5.2 score on scaleStandard Deviation 1.2
VICRYL* Plus SutureMean Cosmetic Outcome Score on Modified Hollander Scale5.7 score on scaleStandard Deviation 0.8
Secondary

Mean Cosmetic Outcome Score on Modified Hollander Scale

Post-operative cosmetic outcome assessed on surgical site by investigator using the modified Hollander Cosmetic Scale (mHCS) with 0 representing worst and 6 representing best, calculated by adding the individual scores on each of 6 categories (step-off borders, contour irregularities, wound margin separation, edge inversion, excessive inflammation, and overall appearance

Time frame: 30 days

Population: Intention to treat (ITT)

ArmMeasureValue (MEAN)Dispersion
Chinese Silk SutureMean Cosmetic Outcome Score on Modified Hollander Scale5.0 score on scaleStandard Deviation 1.2
VICRYL* Plus SutureMean Cosmetic Outcome Score on Modified Hollander Scale5.7 score on scaleStandard Deviation 0.5
Secondary

Mean Surgical Site Infection Score on Modified ASEPSIS Scale

Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst)

Time frame: Day 3

Population: Intention to treat (ITT)

ArmMeasureValue (MEAN)Dispersion
Chinese Silk SutureMean Surgical Site Infection Score on Modified ASEPSIS Scale1.6 score on scaleStandard Deviation 1.3
VICRYL* Plus SutureMean Surgical Site Infection Score on Modified ASEPSIS Scale1.2 score on scaleStandard Deviation 1.3
Secondary

Mean Surgical Site Infection Score on Modified ASEPSIS Scale

Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst)

Time frame: Day 5

Population: Intention to treat (ITT)

ArmMeasureValue (MEAN)Dispersion
Chinese Silk SutureMean Surgical Site Infection Score on Modified ASEPSIS Scale1.5 score on scaleStandard Deviation 1.3
VICRYL* Plus SutureMean Surgical Site Infection Score on Modified ASEPSIS Scale1.2 score on scaleStandard Deviation 1.4
Secondary

Mean Surgical Site Infection Score on Modified ASEPSIS Scale

Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst)

Time frame: Day 7

Population: Intention to treat (ITT)

ArmMeasureValue (MEAN)Dispersion
Chinese Silk SutureMean Surgical Site Infection Score on Modified ASEPSIS Scale1.4 score on scaleStandard Deviation 1.3
VICRYL* Plus SutureMean Surgical Site Infection Score on Modified ASEPSIS Scale0.9 score on scaleStandard Deviation 1.3
Secondary

Mean Surgical Site Infection Score on Modified ASEPSIS Scale

Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst)

Time frame: Day 12

Population: Intention to treat (ITT)

ArmMeasureValue (MEAN)Dispersion
Chinese Silk SutureMean Surgical Site Infection Score on Modified ASEPSIS Scale4.6 score on scaleStandard Deviation 3.6
VICRYL* Plus SutureMean Surgical Site Infection Score on Modified ASEPSIS Scale3.3 score on scaleStandard Deviation 3.8
Secondary

Mean Surgical Site Infection Score on Modified ASEPSIS Scale

Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst)

Time frame: Day 30

Population: Intention to treat (ITT)

ArmMeasureValue (MEAN)Dispersion
Chinese Silk SutureMean Surgical Site Infection Score on Modified ASEPSIS Scale4.6 score on scaleStandard Deviation 3.5
VICRYL* Plus SutureMean Surgical Site Infection Score on Modified ASEPSIS Scale3.7 score on scaleStandard Deviation 5.2
Secondary

Mean Surgical Site Infection Score on Modified ASEPSIS Scale

Post-operative assessment of wound by trained observer to identify SSI based on several characteristics that are assigned points that contribute to a total score, with 0-10 representing satisfactory healing (best), 11-20 representing disturbance of healing, 21-30 representing minor wound infection, 31-40 representing moderate wound infection, and over 40 representing severe wound infection (worst)

Time frame: Day 90

Population: Intention to treat (ITT)

ArmMeasureValue (MEAN)Dispersion
Chinese Silk SutureMean Surgical Site Infection Score on Modified ASEPSIS Scale4.3 score on scaleStandard Deviation 3.3
VICRYL* Plus SutureMean Surgical Site Infection Score on Modified ASEPSIS Scale3.2 score on scaleStandard Deviation 3.6

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026